Reuters logo
BRIEF-Medgenics enters collaboration with Kyowa Hakko Kirin
2016年6月6日 / 上午11点22分 / 1 年前

BRIEF-Medgenics enters collaboration with Kyowa Hakko Kirin

June 6 (Reuters) - Medgenics Inc :

* Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko’s anti-light monoclonal antibody

* Data from signal finding study in severe pediatric onset inflammatory bowel disease patients expected in first half 2017

* Upon completion of signal finding study in severe pediatric onset IBD, company will have option to license rights to develop program

* Following exercise of option, medgenics will make a one-time, upfront payment in low single-digit millions to Kyowa Hakko Kirin

* Co to have commercialization rights in U.S., Canada, will also add rights in europe if Kyowa Hakko Kirin selects licensing arrangement Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below